足白癬の世界市場：疾患タイプ別、治療タイプ別、投与経路別、流通チャネル別、地域別

世界の足白癬市場は、2025年には14億1,000万米ドルと推定され、2032年には19億9,000万米ドルに達すると予測され、2025年から2032年にかけてCAGR5.0％で成長する見込みです。

図.足白癬の世界市場シェア（%）、2025年地域別

足白癬としても知られる足白癬は、足の皮膚、特に足の指の間を侵す一般的な真菌感染症であるが、足の爪や手にも広がることがあります。真菌は、スポーツをする人によく見られる汗をかいた靴の中など、暖かく湿った環境で繁殖するため、スポーツ選手によく見られることから足白癬と名付けられました。この症状の特徴は、足の指の間や足の裏のかゆみ、チクチク感、灼熱感です。患部の皮膚は赤くなり、カサカサしたり、ひび割れたり、水ぶくれになったりすることもあります。不快な症状ではあるが、一般的には軽度であり、市販の抗真菌薬で治療可能です。しつこい場合や重症の場合は、処方箋による強力な治療が必要になることもあります。足白癬は、皮膚糸状菌（皮膚の古い表皮で増殖する真菌の一種）によって引き起こされます。この真菌は、汚染された表面との直接的な接触や、タオル、靴、衣服などとの間接的な接触によって容易に広がります。共同シャワー、プール、ロッカールームはトランスミッションのホットスポットであり、アスリートやジム通いの人は特に感染しやすいです。足白癬の予防には、足の衛生管理が重要な役割を果たします。これには、足を清潔で乾燥した状態に保つこと、通気性の良い靴を履くこと、靴下を定期的に履き替えること、真菌が存在する可能性のある公共の場所では裸足で歩かないことなどが含まれます。また、足白癬の人は、体の他の部分や他の人に感染を広げないように注意する必要があります。足白癬の早期発見・早期治療は、感染症の管理が難しくなったり、より重篤な二次的な細菌感染につながったりするのを防ぐために重要です。原因、予防、治療法を理解することで、この症状に効果的に対処し、足の健康を維持することができます。

市場力学：

世界の足白癬市場は、主に高齢者人口の増加、肥満率の増加、水遊びへの参加の増加による感染症の有病率の上昇が牽引しています。未治療の足の真菌感染症の影響に関する健康意識の高まりも、自己診断と市販薬を後押ししています。しかし、市販の（OTC）外用クリームやパウダーを使用した家庭療法などの代替治療オプションは、処方薬の収益創出の可能性を妨げる可能性があります。

本調査の主な特徴

• 本レポートでは、世界の足白癬市場を詳細に分析し、2024年を基準年とした予測期間（2025～2032年）の市場規模および複合年間成長率（CAGR）を掲載しています。
• また、さまざまなセグメントにわたる潜在的な収益機会を明らかにし、この市場の魅力的な投資提案マトリクスについて解説しています。
• また市場促進要因、抑制要因、機会、新製品の上市や承認、市場動向、地域別の展望、主要企業が採用する競争戦略などに関する主要考察も提供しています。
• 世界の足白癬市場における主要企業プロファイルを、企業ハイライト、製品ポートフォリオ、主要なハイライト、業績、戦略などのパラメータに基づいて掲載しています。
• このレポートからの洞察により、マーケティング担当者や企業の経営陣は、将来の製品発売、タイプアップ、市場拡大、マーケティング戦術に関する情報に基づいた意思決定を行うことができます。
• 世界の足白癬市場レポートは、投資家、サプライヤー、製品メーカー、流通業者、新規参入者、財務アナリストなど、この業界の様々な利害関係者に対応しています。
• 利害関係者は、世界の足白癬市場の分析に使用される様々な戦略マトリックスを通じて、意思決定が容易になります。

目次

第1章 調査の目的と前提条件

• 調査目的
• 前提条件
• 略語

第2章 市場の展望

• レポートの説明
  • 市場の定義と範囲
• エグゼクティブサマリー
• Coherent Opportunity Map（COM）

第3章 市場力学、規制、動向分析

• 市場力学
  • 促進要因
• 健康と衛生意識の高まり
• パーソナルケアとスポーツヘルスケアへの支出の増加
• 治療選択肢における技術的進歩
• 主なハイライト
• 規制シナリオ
• 最近の動向
• 製品の発売/承認
• PEST分析
• PORTERの分析
• 合併、買収、および提携

第4章 世界の足白癬市場- コロナウイルス（COVID-19）パンデミックの影響

• COVID-19疫学
• 供給側と需要側の分析
• 経済への影響

第5章 世界の足白癬市場、薬剤クラス別、2020年～2032年

• 抗真菌薬
• 併用

第6章 世界の足白癬市場、疾患別、2020年～2032年

• 指間
• 足底
• 小胞状

第7章 世界の足白癬市場、投与経路別、2020年～2032年

• 外用
• 経口

第8章 世界の足白癬市場、流通チャネル別、2020年～2032年

• 病院薬局
• 小売薬局
• オンライン薬局

第9章 世界の足白癬市場、地域別、2020年～2032年

• 北米
• 欧州
• アジア太平洋
• ラテンアメリカ
• 中東
• アフリカ

第10章 競合情勢

• 企業プロファイル
  • Perrigo Company Plc.
  • Novartis AG
  • Valeant Pharmaceuticals International
  • GlaxoSmithKline plc
  • Bayer AG
  • Teva Pharmaceuticals Industries Ltd.
  • Mylan NV
  • Glenmark Pharmaceutical Ltd
  • Taro Pharmaceutical Industries Ltd.
  • Camber Pharmaceuticals Inc
  • Aurobindo Pharma Ltd

第11章 セクション

• 参考文献
• 調査手法
• 出版社について

Global Athlete's foot Market is estimated to be valued at USD 1.41 Bn in 2025 and is expected to reach USD 1.99 Bn by 2032, growing at a compound annual growth rate (CAGR) of 5.0% from 2025 to 2032.

Figure. Global Athlete's foot Market Share (%), By Region 2025

Athlete's foot, also known as tinea pedis, is a common fungal infection that affects the skin on the feet, particularly the spaces between the toes, but can also spread to the toenails and hands. It is named athlete's foot because it is frequently seen in athletes, as the fungus thrives in warm, moist environments, such as the inside of sweaty shoes, which are common among sports participants. This condition is characterized by itching, stinging, and burning sensations between the toes or on the soles of the feet. The affected skin may also become red, flaky, cracked, or blistered. Although the condition can be uncomfortable, it is generally mild and can be treated with over-the-counter antifungal medications. In persistent or severe cases, prescription-strength treatments may be necessary. Athlete's foot is caused by dermatophytes, a type of fungus that grows on the dead outer layer of skin. The fungus spreads easily through direct contact with contaminated surfaces or through indirect contact with towels, shoes, or clothing. Communal showers, swimming pools, and locker rooms are hotspots for transmission, making athletes and gym-goers particularly susceptible. Good foot hygiene plays a crucial role in preventing athlete's foot. This includes keeping the feet clean and dry, wearing breathable footwear, changing socks regularly, and avoiding walking barefoot in public places where the fungus may be present. Individuals with athlete's foot should also be careful not to spread the infection to other parts of their body or to other people. Early detection and treatment of athlete's foot are important to prevent the infection from becoming more difficult to manage or leading to more serious secondary bacterial infections. Understanding the causes, prevention, and treatment options enables individuals to effectively deal with this condition and maintain good foot health.

Market Dynamics:

The global athlete's foot market is primarily driven by the rising prevalence of the infection due to a growing geriatric population, increasing obesity rates, and greater participation in aquatic activities. Growing health awareness regarding implications of untreated fungal infections of feet is also supporting self-diagnosis and over-the-counter medication. However, alternative treatment options such as home remedies using over-the-counter (OTC) topical creams and powders may hinder revenue generation potential for prescription drugs.

Key features of the study:

• This report provides in-depth analysis of the global athlete's foot market, and provides market size (US$ Bn) and compound annual growth rate (CAGR %) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global athlete's foot market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Perrigo Company Plc., Novartis AG, Valeant Pharmaceuticals International, GlaxoSmithKline plc, Bayer AG, Teva Pharmaceuticals Industries Ltd., Mylan NV, Glenmark Pharmaceutical Ltd, Taro Pharmaceutical Industries Ltd., Camber Pharmaceuticals Inc, Aurobindo Pharma Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global athlete's foot market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global athlete's foot market

Detailed Segmentation:

• Global Athlete's Foot Market, By Drug Class
  • Antifungals
  • Combination
• Global Athlete's Foot Market, By Disease Indication
  • Interdigital
  • Plantar
  • Vesicular
• Global Athlete's Foot Market, By Route of Administration
  • Topical
  • Oral
• Global Athlete's Foot Market, By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Athlete's Foot Market, By Region
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
• Company Profiles
  • Perrigo Company Plc.
  • Novartis AG
  • Valeant Pharmaceuticals International
  • GlaxoSmithKline plc
  • Bayer AG
  • Teva Pharmaceuticals Industries Ltd.
  • Mylan NV
  • Glenmark Pharmaceutical Ltd
  • Taro Pharmaceutical Industries Ltd.
  • Camber Pharmaceuticals Inc
  • Aurobindo Pharma Ltd

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Athlete's Foot, By Drug Class
  • Market Athlete's Foot, By Disease Indication
  • Market Athlete's Foot, By Route of Administration
  • Market Athlete's Foot, By Distribution Channel
  • Market Athlete's Foot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Driver
• Growing health and hygiene awareness
• Increasing spending on personal care and sports healthcare
• Technological advancements in treatment options
• Key Highlights
• Regulatory Scenario
• Recent Trends
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Mergers, Acquisitions, and Collaborations

4. Global Athlete's Foot Market- Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Supply Side and Demand Side Analysis
• Economic Impact

5. Global Athlete's Foot Market, By Drug Class, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Antifungals
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Combination
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

6. Global Athlete's Foot Market, By Disease Indication, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021-2032
  • Segment Trends
• Interdigital
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Plantar
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Vesicular
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

7. Global Athlete's Foot Market, By Route of Administration, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Region, 2021-2032
  • Segment Trends
• Topical
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

8. Global Athlete's Foot Market, By Distribution Channel, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Region, 2021-2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

9. Global Athlete's Foot Market, By Region, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, By Country, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Country 2020 -2032
  • Country Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
    • U.S.
    • Canada
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2032,(US$ Bn)
    • South Africa
    • North Africa
    • Central Africa

10. Competitive Landscape

• Company Profile
  • Perrigo Company Plc.
• Drug Class Portfolio
• Key Developments
• Financial Performance
• Strategies
  • Novartis AG
• Drug Class Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Valeant Pharmaceuticals International
• Drug Class Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • GlaxoSmithKline plc
• Company Highlights
• Drug Class Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Bayer AG
• Company Highlights
• Drug Class Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Teva Pharmaceuticals Industries Ltd.
• Company Highlights
• Drug Class Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Mylan NV
• Company Highlights
• Drug Class Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Glenmark Pharmaceutical Ltd
• Company Highlights
• Drug Class Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Taro Pharmaceutical Industries Ltd.
• Company Highlights
• Drug Class Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Camber Pharmaceuticals Inc
• Company Highlights
• Drug Class Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Aurobindo Pharma Ltd
• Company Highlights
• Drug Class Portfolio
• Key Highlights
• Financial Performance
• Strategies
• Analyst Views

11. Section

• References
• Research Methodology
• About us